Gene therapy · developed by Pfizer
Fordadistrogene movaparvovec is a gene therapy studied in Duchenne muscular dystrophy.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05689164 | Phase 3 | Duchenne Muscular Dystrophy | Terminated | PFE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Duchenne Muscular Dystrophy
Updated Nov 15, 2026. Something wrong or missing? Report it on the PFE page.
See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PFE catalysts and pipeline →